Sensitizers and protectors of radiation and chemotherapy

Current Problems in Cancer

Volumn 25, Issue 6, 2001, Pages 329-412

  Poggi, Matthew M ^a   Coleman, C Norman ^a   Mitchell, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; AMIFOSTINE; ETANIDAZOLE; METRONIDAZOLE; MISONIDAZOLE; NIMORAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; PROSTAGLANDIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CYTOTOXICITY; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; ADJUVANT CHEMOTHERAPY; ANIMAL; CLINICAL TRIAL; NEOPLASM; SENSITIVITY AND SPECIFICITY;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; NEOPLASMS; PROSTAGLANDINS, SYNTHETIC; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; SENSITIVITY AND SPECIFICITY;

EID: 0035669024     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcn.2001.120122     Document Type: Review

References (453)

1. Radiation Modifiers
2. Initial events in the cellular effects of ionizing radiations: Clustered damage in DNA
3. Track structure in radiation biology: Theory and applications
4. Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the adaptive response and cannot be explained by a subpopulation of sensitive cells
5. Induction of stress genes by low doses of gamma rays
6. Current scientific issues related to clinical radiation oncology
7. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours
8. Radiation and high-dose metronidazole in supratentorial glioblastomas
9. Principles of chemoradiation: Theoretical and practical considerations
10. The action of colchicine on cell division in human cancer, animal, and plant tissues
11. The antileukemic action of combinations of certain known antileukemic agents
12. Studies of fluorinated pyrimidines. II. Effects of transplanted tumors
13. Combined chemotherapy and irradiation in inoperable bronchogenic carcinoma
14. A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer
15. Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation
16. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestional cancer
17. Combined therapy for cancer of the anal canal: A preliminary report
18. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues
19. The combination of radiotherapy and chemotherapy: A review
20. The hazard of accelerated tumor clonogen repopulation during radiotherapy
21. Terminology for chemoradiation effects
22. Radiation-chemotherapy interactions
23. The relative radiosensitivity of the nucleus and cytoplasm of the Chinese hamster fibroblasts
24. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells
25. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs
26. Mechanism of radiosensitization by halogenated pyrimidines: The contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells
27. Potentially lethal damage versus sublethal damage: Independent repair processess in actively growing Chinese hamster cells
28. Action of x-rays on mammalian cells
29. The dose-rate effect in human tumour cells
30. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells
31. Hydroxyurea revisited: A decade of clinical effects studies
32. Taxol sensitizes human astrocytoma cells to radiation
33. In vitro studies of paclitaxel (Taxol) as a radiation sensitizer in human tumor cells
34. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma
35. Clinical radiosensitization: Why it does and does not work
36. Assessment of human tumour proliferation using bromodeoxyuridine - Current status
37. Fractionation studies with WR-2721: Normal tissues and tumour
38. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and topopherol
39. Potential use of nitroxides in radiation oncology
40. Evaluation of Tempol radioprotection in a murine tumor model
41. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model
42. Barriers to drug delivery in solid tumors
43. Multidrug resistance in cancer
44. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells
45. Antagonism of paclitaxel cytotoxicity by x-rays: Implications for the sequence of combined modality therapy
46. Modification of tumour blood flow: Current status and future directions
47. Concepts of oxygen transport at the microcirculatory level
48. The histological structure of some human lung cancers and the possible implications for radiotherapy
49. Transvascular drug delivery in solid tumors
50. Tumor pH: Implications for treatment and novel drug design
51. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
52. Chinese hamster pleiotropic multidrugresistant cells are not radioresistant
53. The concept of immunological surveillance
54. The stromal reaction of tumors: An expression of immune surveillance
55. A morphometric analysis of human breast carcinoma
56. Laser-capture microdissection: Opening the microscopic frontier to molecular analysis
57. Microdissection, microchip arrays, and molecular analysis of tumor cells (primary and metastases)
58. Tumor radioresistance in clinical radiotherapy
59. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves
60. Hypoxic cell radiosensitizers: Expectations and progress in drug development
61. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers
62. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland
63. Measurement of tumor oxygenation
64. The tumor microenvironment: A double-edged sword
65. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma
66. A multicomponent x ray survival curve for mouse lymphosarcoma cells irradiated in vivo
67. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data
68. Hypoxic fractions of human tumors xenografted into mice: A review
69. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
70. 2 tension measurements
71. 2 predicts survival in advanced cancer of the uterine cervix
72. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
73. Techniques to assess the oxygenation of human tumors. State of the art
74. Oxygenation predicts radiation response and survival in patients with cervix cancer
75. Hypoxic regions exist in human prostate carcinoma
76. Oxygenation of human tumors: The Mainz experience
77. A marker for hypoxic cells in tumours with potential clinical applicability
78. Binding of misonidazole to EMt6 and V79 spheroids
79. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors
80. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia
81. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors
82. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts
83. Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
84. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells
85. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "Comet" assay
86. Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay
87. Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay
88. Radiation-induced DNA base damage detected in individual aerobic and hypoxic cells with endonuclease III and formamidopyrimidine-glycosylase
89. Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia
90. Correlations between in vivo 31P NMR spectroscopy measurements, tumor size, hypoxic fraction and cell survival after radiotherapy
91. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice
92. Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation
93. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia
94. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow
95. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging
96. On a novel MRI technique (OMRI) for the determination of tissue parameters
97. Overhauser-enhanced MR imaging (OMRI)
98. Three-dimensional whole body imaging of spin probes in mice by time-domain radiofrequency electron paramagnetic resonance
99. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
100. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients
101. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
102. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia
103. Oxygenation of carcinomas of the uterine cervix: Evaluation by computerized O2 tension measurements
104. Oxygenation status of breast cancers: The Mainz experience
105. Oxygenation of human tumors: The Aarhus experience
106. Human tumor oxygenation: The Duke University Medical Center experience
107. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas
108. Oxygenation of human tumors: The Munich/Halle experience
109. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
110. Tumor oxygenation: The Institut Gustave Roussy experience
111. The impact of tumor oxygenation on clinical radiation oncology
112. Modulation of tumor oxygenation and radiosensitivity by erythropoietin
113. Clinical trial experience using erythropoietin during radiation therapy
114. Cervix cancer oxygenation measured following external radiation therapy
115. Chemical modifiers of cancer treatment
116. Joint oxygen-glucose deprivation as the cause of necrosis in a tumor analog
117. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours
118. The use of fluorescent probes to identify regions of transient perfusion in murine tumors
119. Acute hypoxia in tumors: Implications for modifiers of radiation effects
120. Intermittent blood flow in a murine tumor: Radiobiological effects
121. Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response
122. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse
123. An estimation of changes in the proportions and absolute numbers of hypoxic cells after irradiation of transplanted C3H mousemammary tumours
124. Oxygenation status of a transplantable tumor during fractionated radiation therapy
125. Direct measurement of moxygenation in malignant mammary tumors after a single large dose of irradiation
126. Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation
127. Temporal changes in pO2 of R3230AC tumors in Fischer-344 rats
128. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy
129. The effect of extreme hypoxia and glucose on the repair of potentially lethal and sublethal radiation damage by mammalian cells
130. The effect of pH on potentially lethal damage recovery in A549 cells
131. Effects of reoxygenation on cells from hypoxic regions of solid tumors: Anticancer drug sensitivity and metastatic potential
132. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines
133. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia
134. The radiation response of cells recovering after chronic hypoxia
135. Enhancement of radiation sensitivity by postirradiation hypoxia: Time course and oxygen concentration dependency
136. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells
137. Effects of reoxygenation on cells from hypoxic regions of solid tumors: Analysis of transplanted murine tumors for evidence of DNA overreplication
138. The influence of tumor hypoxia on malignant progression
139. Characterization of hypoxia-inducible factor1 and regulation of DNA binding activity by hypoxia
140. Hypoxia-mediated gene expression
141. Perspectives on oxygen sensing
142. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases
143. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target
144. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes
145. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
146. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma
147. Comparison between in vitro radiosensitivity and in vivo radioresponse of murine tumor cell lines - I: Parameters of in vitro radiosensitivity and endogenous cellular glutathione levels
148. Radionuclide toxicity in cultured mammalian cells. Elucidation of the primary site for radiation-induced division delay
149. Constraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks
150. Comparative effect of the thiols dithiothreitol, cysteamine and WR-151326 on survival and on the induction of DNA damage in cultured Chinese hamster ovary cells exposed to gamma-radiation
151. The relationship of DNA and chromosome damage to survival of synchronized X-irradiated L5178Y cells - II: Repair
152. Induction of chromosomal aberrations and sister chromatid exchanges by alpha particles in density-inhibited cultures of mouse 10T1/2 and 3T3 cells
153. X-ray-induced breakage and rejoining of human interphase chromosomes
154. A comparison of the chemical repair rates of free radical precursors of DNA damage and cell killing in Chinese hamster V79 cells
155. Of what use is molecular biology to the practicing radiation oncologist?
156. Free radical repair mechanisms and the interaction of glutathione and vitamins C and E
157. Potential limitation to hydrogen atom donation as a mechanism of repair in chemical models of radiation damage
158. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity
159. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer
160. d,1-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors
161. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721
162. Radiosensitization in multifraction schedules - II: Greater sensitization by 2-nitroimidazoles than by oxygen
163. The effects of misonidazole and continuous low dose irradiation
164. The production of strand breaks in DNA in the presence of the hydroxylamine of SR-2508 (1-[N-(2-hydroxyethyl)acetamido]-2-nitroimidazole) at neutral pH
165. Depletion of intracellular glutathione by 1-methyl-2-nitrosoimidazole
166. Radiation and chemotherapy sensitizers and protectors
167. Combination of taxanes with radiation: Preclinical studies
168. Concurrent paclitaxel and radiation therapy in the treament of solid tumors
169. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer: Thoracic Oncology Program
170. Radiosensitization by gemcitabine
171. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives
172. Topoisomerase I inhibitors in the treatment of colorectal cancer
173. DNA topoisomerase I-targeting drugs as radiation sensitizers
174. Misonidazole - A drug for trial in radiotherapy and oncology
175. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer
176. Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy
177. Misonidazole combined with splitcourse radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study
178. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck
179. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 8005
180. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma
181. Initial pharmacology and toxicology of intravenous desmethylmisonidazole
182. Pharmacokinetic considerations in radiosensitizer development
183. The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers
184. SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
185. Clinical perspectives for the use of new hypoxic cell sensitizers
186. Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug schedule
187. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile
188. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment
189. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: Results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer
190. Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer
191. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
192. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas
193. Hypoxic cell radiosensitizers: The end of an era?
194. Reports of my death [may be] greatly exaggerated (adapted from Mark Twain)-in response to Dr. J. M. Brown
195. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial
196. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27
197. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): A Radiation Therapy Oncology Group study
198. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: A new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
199. Distribution of etanidazole into human brain tumors: Implications for treating high grade gliomas
200. Clinical trials of etanidazole (SR 2508): RTOG and Joint Center for Radiation Therapy trials
201. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG protocol 90-20)
202. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma
203. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer: A one-institution study
204. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer
205. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support
206. The uptake of the radiosensitizing compound Ro 03-8799 (pimonidazole) in human tumors
207. Ro 03-8799: Preferential relative uptake in human tumor xenografts compared to a murine tumor: Comparison with SR-2508
208. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues
209. Radiotherapy, carcinoma of cervix, and the radiosensitizer Ro-03-8799 (pimonidazole)
210. Tumor blood flow changes induced by chemical modifiers of radiation response
211. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo
212. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma: First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85
213. The Danish Head and Neck Cancer Study Group (DAHANCA) randomized trials with hypoxic radiosensitizers in carcinoma of the larynx and pharynx
214. A randomized double-blind phase II study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85
215. Pilot study of nimorazole as a hypoxic-cell-sensitizer with the "chart" regimen in head and neck cancer
216. A phase I study of a hypoxic cell sensitizer KU2285 in combination with conventional radiotherapy
217. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy
218. Intratumoral and parametrial infusion of a 3-nitrotriazole (AK-2123) in the radiotherapy of the uterine cervix cancer: Stage II-III - Preliminary positive results
219. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo
220. Analogues of RSU-1069: Radiosensitization and toxicity in vitro and in vivo
221. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor
222. Experimental pharmacokinetics of RSU-1069 and its analogues: High tumor/plasma ratios
223. RSU 1069, a nitroimidazole containing an aziridine group: Bioreduction greatly increases cytotoxicity under hypoxic conditions
224. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069
225. Dual function nitroimidazoles less toxic than RSU 1069: Selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908)
226. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents
227. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour
228. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer
229. Sensitization to X ray by 5-chloro-2′-deoxycytidine co-administered with tetrahydrouridine in several mammalian cell lines and studies of 2′-chloro derivatives
230. Radiosensitizing nucleosides
231. X-ray sensitization by halopyrimidines
232. The use of halogenated thymidine analogs as clinical radiosensitizers: Rationale, current status, and future prospects: Nonhypoxic cell sensitizers
233. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy
234. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine
235. Intra-arterial 5-bromodeoxyuridine and x-ray therapy
236. A phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation
237. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR)
238. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR
239. Clinical experience with intravenous radiosensitizers in unresectable sarcomas
240. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer
241. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer
242. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation
243. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: A phase I and drug incorporation study
244. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases
245. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation
246. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine
247. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases
248. Halogenated pyrimidines as radiosensitizers for high grade glioma: Revisited
249. Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California Cancer Center phase II study
250. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I-II study
251. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
252. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group Trial (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
253. Iododeoxyuridine radiosensitization by low- and high-energy photons for brachytherapy dose rates
254. Low dose rate irradiation and halogenated pyrimidine effects on human cervical carcinoma cells
255. Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma
256. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma
257. Intravenous delivery of 5′-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: Results of a pilot study
258. Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues
259. Increased chromosome exchange frequencies in iodo-deoxyuridine-sensitized human SW-1573 cells after gammairradiation
260. Therapeutic attack of hypoxic cells of solid tumors: Presidential address
261. Bioreductive drugs as post-irradiation sensitizers: Comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9
262. Keynote address: Hypoxic cell radiosensitizers: Where next?
263. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumors
264. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
265. Pre- and post-irradiation radiosensitization by SR 4233
266. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity
267. Repair of damage induced by SR 4233
268. Evaluation of bioreductive drugs in multicell spheroids
269. The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award Lecture
270. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation
271. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins
272. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
273. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones
274. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
275. SR 4233: A tumor specific radiosensitizer active in fractionated radiation regimes
276. Therapeutic advantage of hypoxic cells in tumors: A theoretical study
277. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation
278. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation
279. Two or six hyperthermia treatments as an adjunct to radiation therapy yield similar tumor responses: Results of a randomized trial
280. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
281. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
282. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks
283. Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: Role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air
284. Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron
285. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
286. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: Pharmacology and activity in vitro and in vivo
287. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice
288. Evaluation of ocular safety: Tirapazamine plus cisplatin in patients with metastatic melanomas
289. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors
290. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study
291. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study
292. Phase II trial of escalated dose of tirapazamine with cisplatin in advance malignant melanoma
293. Bioreductive mechanisms
294. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents
295. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09
296. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP, and cyclophosphamide in vivo
297. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation
298. Bioreductive therapies: An overview of drugs and their mechanisms of action
299. Enhancement of the antitumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
300. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-n-oxide prodrug
301. High-pressure oxygen and radiotherapy
302. Hyperbaric oxygen: The Medical Research Council trials and their clinical significance
303. Does hyperbaric oxygen have a future in radiation therapy?
304. Hyperbaric oxygen therapy for carcinoma of the cervix - Stages IIB, IIIA, IIIB and IVA: Results of a randomized study by the Radiation Therapy Oncology Group
305. Carbogen breathing during radiation therapy - The Radiation Therapy Oncology Group Study
306. Changes in the oxygenation of head and neck tumors during carbogen breathing
307. The significance of anemia in clinical radiation therapy
308. Hemoglobin, radiation, morbidity and survival
309. A clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neck
310. Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck
311. Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors
312. Hypoxia and local tumour control: Part 2
313. Radiotherapy and anaemia - The clinical experience
314. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
315. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13
316. Erythropoietin for patients undergoing radiotherapy: A pilot study
317. Biochemical modifiers: Hypoxic cell sensitizers
318. Tissue oxygen manipulation and tumor blood flow
319. Heterogeneity in tumor microvascular response to radiation
320. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber
321. Drug induced perturbations in tumor blood flow: Therapeutic potential and possible limitations
322. Effects of hydralazine on in vivo tumor energy metabolism, hematopoietic radiation sensitivity, and cardiovascular parameters
323. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay
324. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy
325. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: Effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069
326. The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts
327. Relationship between the hydralazineinduced changes in murine tumor blood supply and mouse blood pressure
328. Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue
329. The effects of single dose oral hydralazine on blood flow through human lung turnouts
330. Nicotinamide as a radiosensitizer of a C3H mouse mammary adenocarcinoma
331. Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy
332. Calcium antagonists as radiation modifiers: Site specificity in relation to tumor response
333. Effect of flunarizine on micro-regional distributions of intravascular HbO2 saturations in RIF-1 and KHT sarcomas
334. Increase in tumor oxygenation and radiosensitivity caused by pentoxifylline
335. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide
336. Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy
337. Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer
338. Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial
339. Carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: Long-term tumor control and complications
340. Efficacy of agents counteracting hypoxia in fractionated radiation regimes
341. Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide
342. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation
343. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: A new modality treatment
344. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer Trial 22933
345. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: A feasibility study
346. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: The experience of the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer
347. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide
348. Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: A 99mTc-HMPAO SPECT study
349. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide
350. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: Oxygenation and tumour control studies
351. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation
352. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor
353. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality
354. Basic fibroblast growth factor radioprotects bone marrow and not RIF1 tumor
355. The role of cytokines in the development of normal-tissue reactions after radiotherapy
356. Cysteine protection against X-irradiation
357. Can WR-2721 be improved upon?
358. Radiation protectors: The unexpected benefits
359. Differential chemoprotection of normal and malignant tissues
360. On the potential application of radioprotective drugs in radiotherapy
361. Radiobiolgoical and biochemical studies of thiophosphate radioprotective compounds related to cysteamine
362. Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments
363. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721
364. Radioprotection of tumor and normal tissues by thiophosphate compounds
365. Efficacy testing of WR-2721 in Great Britain everything is black and white at the gray lab
366. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study
367. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties
368. Intraoperative radiotherapy with localized radioprotection: Diminished duodenal toxicity with intraluminal WR2721
369. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
370. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
371. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721
372. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anticytotoxic and anti-mutagenic mechanisms of action
373. Radioprotectants: Pharmacology and clinical applications of amifostine
374. Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection
375. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine
376. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065
377. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin
378. Modification of the radiation response of the mouse kidney by misonidazole and WR-2721
379. A comparative study of the radioprotective effects of cysteamine, WR-2721, and WR-1065 in cultured human cells
380. Dephosphorylation of WR-2721 with mouse tissue homogenates
381. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug
382. Hydrolysis of WR2721 by mouse liver cell fractions
383. Rat liver alkaline phosphatases. Evidence hepatocyte and portal triad enzymes differ
384. Pharmacokinetics of WR-2721
385. Modification of the radiation response of the mouse kidney by misonidazole and WR-2721
386. Radioprotection of mouse skin by WR-2721: The critical influence of oxygen tension
387. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
388. Final report of the phase I trial of singledose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]
389. Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity
390. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689)
391. Specific protection of different normal tissues
392. Human pharmacokinetics of WR-2721
393. An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma
394. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721
395. Hydrolysis of S-2-(3-aminopropylamino)ethylphosphorothioate (WR-2721)
396. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent)
397. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid
398. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy
399. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy: The New York Gynecologic Oncology Group
400. Use of radiation with or without WR-2721 in advanced rectal cancer
401. Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine
402. Topical application of WR-2721 achieves high concentrations in the rectal wall
403. Future directions in toxicity prevention
404. Final report of a phase III randomized trial of amifostine as a radiprotectant in head and neck cancer
405. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebocontrolled study
406. Phase I/II trials of WR-2721 and cis-platinum
407. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
408. Phase I controlled trials of WR-2721 and cyclophosphamide
409. High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma: A phase II study
410. Phase I study of WR-2721 and carboplatin
411. WR-2721 pretreatment protects against the marrow toxicity of carboplatin and cisplatin
412. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York Gynecologic Oncology Group study
413. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
414. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors
415. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
416. Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine
417. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival
418. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable nonsmall-cell lung cancer: Results of a phase II trial
419. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
420. American Society of Clinical Oncology Clinical Practice Guidelines for the use of chemotherapy and radiotherapy protectants
421. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, Tempol
422. Action of radiation on mammalian cells: III. Relationships between reproductive death and induction of chromosome anomalies by X-irradiation of euploid human cells in vitro
423. Chromosome aberrations and radiation-induced cell death: II. Predicted and observed cell survival
424. Radiation-induced cellular reproductive death and chromosome aberrations
425. Nitroxide-mediated protection against x-ray- and neocarzinostatin-induced DNA damage
426. Protection of radiation-induced chromosomal aberrations by the nitroxide Tempol
427. Tempol, a stable free radical, is a novel murine radiation protector
428. Principles of the metabolism of nitroxides and their implications for spin trapping
429. Topical application of nitroxide protects radiation induced alopecia in guinea pigs
430. Protection from radiation-induced alopecia with topical application of nitroxides: Fractionated studies
431. 16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells
432. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial
433. Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice
434. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation
435. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin
436. The prostaglandin E1 analog, misoprostol, a normal tissue protector, does not protect four murine tumors in vivo from radiation injury
437. Eicosanoid-induced radioprotection and chemoprotection of normal tissue during cancer treatment
438. Differential radioprotective effects of misoprostol in DNA repair-proficient and -deficient or radiosensitive cell systems
439. The synthetic somatostain analogue, octreotide, ameliorates acute and delayed intestinal radiation injury
440. Development of functional electron paramagnetic resonance imaging
441. Radiation sensitizers